Sachiyo Minegishi, MBA
Member and Chair of the Audit Committee
Sachiyo Minegishi is a member of the Mural Oncology Board of Directors and serves as chair of the Audit Committee.
Sachiyo brings 20 plus years of experience in the biotechnology industry, with a focus on corporate strategy, finance, development, and commercialization. She is currently Chief Operating Officer at Rectify Pharma. Prior to Rectify, Sachiyo was Chief Financial Officer at Akouos, Inc., where she led corporate finance and business development strategy, and played a key role in the acquisition of the company by Lilly. Before joining Rectify, she was a Global Program Lead at bluebird bio, where she led a team to execute global development and commercialization strategy for a portfolio of gene therapies for sickle cell disease. Sachiyo has also held leadership roles that helped accelerate corporate growth at Aegerion Pharmaceuticals, Human Genome Sciences, Genzyme, and Amgen. She began her career in investment banking at Merrill Lynch, with a focus on execution of equity financing and mergers and acquisitions in the biotechnology industry.
Sachiyo earned a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania.